Sitemap > News > Cardiovascular Disorders
Displaying 1 - 50 of 1252 results
- Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
- Cardiome and Astellas Announce Positive Results from ACT 2 Trial
- Scios Announces Enrollment of First Patients In Ascend-HF Trial in Acute Heart Failure
- Archemix Announces Completion of Phase 1 Trial of ARC1779
- Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
- Pilot Phase 3 Results of NovaCardia’s KW-3902 for Acute Congestive Heart Failure Presented
- Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
- FDA Issues Third Approvable Letter for Thelin (Sitaxsentan Sodium)
- Novo Nordisk and Neose announce initiation of phase 1 clinical trial of long-acting factor VIIa
- Exforge receives final US approval as new and powerful treatment option for patients with high blood pressure
- ALEXION’S SOLIRIS GRANTED MARKETING APPROVAL IN EUROPE FOR TREATMENT OF ALL PATIENTS WITH PNH
- Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar
- Rasilez®, an important new treatment for high blood pressure, receives positive opinion recommending European Union approval
- Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe
- BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
- Benicar HCT Reductions in seated systolic blood pressure for Stage 2 patients compared with Amlodipine benazepril
- Amlodipine and Olmesartan Study Results Released
- Orexigen™ Therapeutics Reports Contrave™ Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes
- GlaxoSmithKline’s Arixtra® (fondaparinux sodium) receives positive opinion in Europe for the treatment of acute coronary syndromes
- Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R &D Event
- Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
- Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
- Vasogen Reports on Outcome of FDA Meeting
- SPEEDEL REPORTS SUCCESSFUL SPP635 PHASE IIA TRIAL IN HYPERTENSION
- Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
- Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Hypertension
- Ablynx announces interim results of first Nanobody® Phase I study of ALX-0081 (anti-vWF)
- Biogen Idec and Cardiokine partner to develop Lixivaptan, a novel vasopressin antagonist
- Anthera Completes Enrollment of "PLASMA" Trial With A-002 and Announces Initiation of new Investigator Study
- Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
- ProMetic reports positive preliminary phase Ib/II data for PBI-1402 in chemotherapy-induced anemia
- CardioVascular BioTherapeutics Authorized to Initiate Phase II Trial of Angiogenesis Therapy for Severe Coronary Heart Disease
- ProMetic reports positive preliminary phase Ib/II data for PBI-1402 in chemotherapy-induced anemia
- Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
- NicOx receives €5 million milestone from Merck & Co., Inc. as drug candidate enters clinic
- Amira Pharmaceuticals Announces Positive Initial Data from a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease
- St. Jude Medical Announces Japanese Approval of CRT-D Products to Treat Heart Failure Patients
- Data Show Overlapping CYPHER® Sirolimus-eluting Coronary Stents Have Better Rates Of Key Clinical Indicators Than Overlapping Bare Metal Stents
- Abbott Enrolls First Patient in World’s First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program of APD791 for the Treatment of Arterial Thrombosis
- FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
- New data show Tekturna and Diovan used together provide additive blood pressure reductions
- Boston Scientific Announces First Implant of TAXUS Element Platinum Chromium Stent
- Mircera approved in European Union for treatment of anaemia related to chronic kidney disease
- Pervasis Therapeutics Successfully Completes Enrollment for Vascugel Phase II Clinical Trials
- Artisan Pharma, Inc. Launches Phase 2b Trial of ART-123 for Treatment of DIC in Sepsis
- Medicure Announces Second Successful DSMB Review for the Phase 3 Mend-CABG II Trial
- Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
- AtheroGenics Announces First Patients Enrolled in ANDES Phase III Diabetes Clinical Trial
- OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval for Thrombin Stand Alone, EVITHROM* Thrombin, Topical (Human), with General Hemostasis in Surgery Indication